Radiofrequency Ablation Devices Market Poised for Steady Growth, Fueled by Innovation and Rising Surgical Volumes | DelveInsight

The Global Radiofrequency Ablation Devices Market was valued at USD 3.64 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.37% between 2024 and 2030, reaching USD 6.19 billion by 2030. This growth is driven by an increasing incidence of chronic conditions such as cardiovascular diseases and cancers, a rising elderly population, and ongoing technological innovations enhancing product design and development.

DelveInsight's Radiofrequency Ablation Devices Market Insights report provides the current and forecast market analysis, individual leading Radiofrequency Ablation Devices companies' market shares, challenges, Radiofrequency Ablation Devices market drivers, barriers, and trends, and key Radiofrequency Ablation Devices companies in the market.

Request for a sample page report @ https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Radiofrequency Ablation Devices Market Report
The Radiofrequency Ablation Devices market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Radiofrequency Ablation Devices market during the forecast period.
Notable Radiofrequency Ablation Devices companies such as BIOTRONIK Schweiz AG, Medtronic, Abbott, Olympus., Stryker, Boston Scientific Corporation, AngioDynamics., CONMED Corporation, Lepu Medical Technology (Beijing) Co., Ltd, Arthrex, Inc., STARmed Co., Ltd., HOLOGIC, INC, Baylis Medical Company, Inc, Medical Devices Business Services, Inc.(Johnson & Johnson), Smith & Nephew, Sutter Medizintechnik GmbH, Bramsys, RF Medical Co., Ltd, OSYPKA AG, Avanos Medical, Inc., and several others are currently operating in the Radiofrequency Ablation Devices market.
In May 2025, Stryker obtained FDA approval for its OptaBlate Basivertebral Nerve Ablation system, a significant advancement in its portfolio of minimally invasive solutions for long-term pain relief targeting vertebrogenic pain.
In March 2025, NeuroOne Medical Technologies accelerated its 510(k) submission to the U.S. Food and Drug Administration (FDA) for trigeminal nerve ablation, with the new target set for May 2025, utilizing the company's OneRF platform.
On September 9, 2024, Autonomix Medical, Inc., a medical device firm focused on precision nerve-targeted therapies, announced positive preliminary results from the first five "lead-in" patients in its ongoing proof-of-concept clinical trial. The study, assessing the safety and effectiveness of transvascular energy delivery to ablate problematic nerves and reduce pain in pancreatic cancer patients, showed encouraging outcomes after 4-6 weeks.
In October 2021, Venclose Inc. received 510(k) clearance from the U.S. FDA for its Maven endovenous radiofrequency ablation (RFA) catheter designed for the minimally invasive treatment of incompetent perforator veins (IPVs).
In August 2020, Biosense Webster, a subsidiary of Johnson & Johnson Medical Devices Companies, was granted the European CE mark approval for its QDOT MICRO radiofrequency (RF) ablation catheter.
In February 2020, Avanos Medical Inc. secured FDA approval for its 80-watt COOLIEF* Radiofrequency (RF) system used in neurological lesion procedures.

To read more about the latest highlights related to the Radiofrequency Ablation Devices market, get a snapshot of the key highlights entailed in the Global Radiofrequency Ablation Devices Market Report https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Radiofrequency Ablation Devices Overview

Radiofrequency Ablation (RFA) devices use high-frequency electrical currents to generate localized heat, which destroys or ablates abnormal tissue. This minimally invasive technique is widely used in medical treatments such as pain management, tumor destruction, and cardiac arrhythmia correction.

Radiofrequency Ablation Devices Market Insights

Among all regions, North America is projected to hold a substantial share of the radiofrequency ablation devices market. This dominance is attributed to the high incidence of chronic pain conditions such as low back pain, neck pain, and arthritis, coupled with an increasing elderly population, greater public awareness of disease management, and the introduction of new products in the region.

The North American market is experiencing growth largely driven by the rising cases of chronic low back pain. According to the Centers for Disease Control and Prevention, approximately 40 million U.S. workers reported experiencing low back pain in 2019. This condition is a major health concern that significantly impairs patients' quality of life.

Radiofrequency ablation is frequently used to disrupt pain signals in spinal nerves and has become a promising treatment for chronic low back pain. Consequently, the expanding number of patients suffering from this condition is expected to boost the demand for RFA devices, thereby fueling growth in the radiofrequency ablation devices market within the country and the broader region.

To know more about why North America is leading the market growth in the Radiofrequency Ablation Devices market, get a snapshot of the Radiofrequency Ablation Devices Market Outlook https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Radiofrequency Ablation Devices Market Dynamics

The radiofrequency ablation devices market is experiencing revenue growth due to the increasing prevalence of chronic diseases, particularly cardiovascular conditions. According to the World Health Organization's 2023 factsheet, cardiovascular diseases (CVDs) are the leading cause of death worldwide, responsible for an estimated 17.9 million deaths annually. CVDs encompass a range of disorders affecting the heart and blood vessels, including coronary heart disease, rheumatic heart disease, and cerebrovascular disease.

Furthermore, data from the World Heart Foundation indicates that by 2030, around 14 to 17 million people in the European Union will be living with atrial fibrillation, with the number in the United States expected to reach 12 million. Radiofrequency ablation is a widely used treatment for atrial fibrillation, and the growing incidence of such cardiovascular conditions is expected to drive increased demand for radiofrequency ablation devices, supporting market growth globally.

Another significant driver of the market is the rising occurrence of various cancers. Liver cancer, one of the most common cancer types, often employs radiofrequency ablation as a treatment option. The GLOBOCAN 2020 study reported approximately 905,677 new liver cancer cases and about 830,180 related deaths worldwide in 2020, highlighting the importance of this treatment method in managing the disease.

Radiofrequency Ablation Devices Market Drivers:
Rising prevalence of chronic diseases such as atrial fibrillation and various cancers

Get a sneak peek at the Radiofrequency Ablation Devices market dynamics @ https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Scope of the Radiofrequency Ablation Devices Market Report:
Coverage: Global
Study Period: 2022 to 2032
Key Radiofrequency Ablation Devices Companies: BIOTRONIK Schweiz AG, Medtronic, Abbott, Olympus., Stryker, Boston Scientific Corporation, AngioDynamics., CONMED Corporation, Lepu Medical Technology (Beijing) Co., Ltd, Arthrex, Inc., STARmed Co., Ltd., HOLOGIC, INC, Baylis Medical Company, Inc, Medical Devices Business Services, Inc.(Johnson & Johnson), Smith & Nephew, Sutter Medizintechnik GmbH, Bramsys, RF Medical Co., Ltd, OSYPKA AG, Avanos Medical, Inc., and others.

Which MedTech key players in the Radiofrequency Ablation Devices market are set to emerge as the trendsetter, explore @ Radiofrequency Ablation Devices Companies https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:

Kritika Rehani
Assistant Manager, Digital Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.